Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Key HIV Studies Influencing My Practice Following CROI 2022—Audio Recap

February 13-16, 2022; Virtual
Listen to expert insights from Daniel R. Kuritzkes, MD, and David A. Wohl, MD, on some of the most clinically relevant new data presented at CROI 2022, including prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.
Daniel R. Kuritzkes, MD
David A. Wohl, MD
Released: March 14, 2022

In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including:

  • Prevention strategies
    • Data on long-acting (LA) cabotegravir for pre-exposure prophylaxis from an additional 1-year unblinded period of HPTN 083
    • Data on the use of a single genome assay for integrase resistance showing that a sensitive HIV-1 RNA assay would have detected infection before integrase strand transfer inhibitor resistance developed in most patients in HPTN 083
    • Metabolic and renal outcomes with islatravir for pre-exposure prophylaxis in the MK8591-016 trial
    • Efficacy of an HIV-1 vaccine regimen in African women in the Imbokodo study
  • LA therapies
    • CALIBRATE study of lenacapavir in treatment-naive patients
    • CAPELLA study of lenacapavir in heavily treatment–experienced patients
    • Efficacy and safety of LA cabotegravir plus rilpivirine every 8 weeks vs every 4 weeks in ATLAS-2M
  • Second-line therapies
    • The VISEND study comparing dolutegravir-based antiretroviral therapy (ART) vs protease inhibitor–basedART for second-line therapy
    • The NADIA study comparing dolutegravir withdarunavir/ritonavir and tenofovir disoproxil fumarate with zidovudine for second-line therapy
  • Comorbidities and cure
    • ACTG A5324 (InMIND) study of ART intensification for cognitive impairment in people with HIV
    • IMPAACT P1107 case of patient with loss of HIV-1–specific antibody response and viral detection following CCR5∆32/∆32 cord/haploidentical transplant


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck & Co., Inc.
ViiV Healthcare

Information on this Educational Activity


Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has reported that he has received funds for research support from Gilead Sciences, Merck, and ViiV Healthcare and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV Healthcare, and ViroStatics.
David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases
Clinical Trials Unit
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

David A. Wohl, MD, has disclosed that he has received funds for research support from Gilead Sciences and Merck and consulting fees from Gilead Sciences, Janssen, Merck, and ViiV.

Program Medium

This program has been made available online.

Related Content

Dr Kenric Ware discusses opportunities to increase PrEP awareness and uptake on college campuses in this podcast from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 31, 2023

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

Dr Kenric Ware discusses how technology and social media can impact PrEP adherence and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 23, 2023

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 20, 2023 Expired: January 19, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings